Wendy’s rejects Trian’s $1.4 billion acquisition offer

Wendy’s Company (NASDAQ: WEN) rejected a $1.4 billion offer from Trian Fund Management at $7.35 a share, according to ActivTrades analyst Ion Jauregui. The activist fund, led by Nelson Peltz, submitted the proposal with Flynn Group, BlueFive Capital and Sixth Street Partners.

What price did Wendy’s reject?

Jauregui reported that an independent committee unanimously rejected the proposal. ActivTrades said the board considers $7.35 to undervalue the fast-food chain’s recovery potential and future earnings, and that independent ownership offers greater long-term value. The analysis does not identify the committee’s members or set out the terms that could lead Wendy’s to negotiate. Wendy’s has rejected the current price, but it has not disclosed what price it would accept.

How does the poison pill work?

ActivTrades described Wendy’s shareholder rights plan as a “poison pill.” The company approved the plan after the bid, ActivTrades reported.

• A 15% ownership threshold determines when the plan takes effect.
• Any investor exceeding that level without board approval can have their stake diluted.
• The plan remains in force until November 3, 2027.

The buyer group already controls 16.3% of Wendy’s shares, according to ActivTrades. The analysis does not explain how the rights plan treats that existing holding. Trian’s existing 16.3% makes the plan’s treatment of current holders more consequential than the headline threshold.

Can Wendy’s recover without a sale?

ActivTrades said Wendy’s has recorded seven consecutive quarters of declining comparable sales. Under CEO Bob Wright, a transformation plan seeks to restore the brand’s appeal through better food, higher marketing investment and operational optimisation. Operational weakness is central to valuation concerns, ActivTrades said. Yet the board argues the company can create more value independently than under Trian’s proposal. The analysis provides no sales, margin or comparable-sales percentages to test that promise. The seven-quarter decline gives Trian a credible argument; the recovery plan remains a claim without operating benchmarks.

Peltz explored a potential Wendy’s acquisition in 2022, but that initiative did not move forward, according to ActivTrades. His renewed attempt with the partner group now opens a path to renewed negotiations or direct confrontation with the board.

What is the market pricing in?

ActivTrades said Wendy’s shares traded around $8.15, about 11% above the rejected $7.35 offer. It interpreted the premium as evidence that the market does not treat the deal as closed and may be pricing a higher bid or competition for control. The shares fell as low as $5.94 in October and then rebounded by more than 30%, according to ActivTrades. The analysis attributed the move to corporate-transaction expectations and the recovery of technical levels. Jauregui wrote: “The current share price rebound is more closely linked to expectations of a corporate transaction than to any demonstrated improvement in fundamentals.” The market is paying for deal optionality, not a proven operating turnaround.

How fragile is the rebound?

ActivTrades’ technical review said Wendy’s traded in a broad $18.50 to $25.00 range from 2020 through 2024. A break below that support at the end of 2024 started a decline of more than 70%, the analysis said. The October low and rapid recovery of the $6.07-$6.82 support zone suggest selling pressure may be exhausted. The shares also regained long-term moving averages at $7.06 and $7.69, according to ActivTrades. Short-term momentum remains positive but stretched. The daily RSI stood around 74, in overbought territory, while the MACD stayed positive with a rising histogram. Technical recovery is real, but the long-term structure remains fragile.

Which price levels matter now?

ActivTrades identified $8.50 as the first resistance level, followed by a $9.00-$9.42 range. A break above that band would open a path toward $10.00, the analysis said. Support sits at $7.69, $7.35, $7.06 and $6.82. The $7.35 level carries special weight because it matches the rejected offer. ActivTrades said trading above $7.35 preserves expectations of an improved bid. A pullback toward that level would not necessarily break the bullish case, but a fall below both $7.06 and $6.82 would signal fading takeover hopes. The $7.35 offer price remains the deal anchor; $7.06 and $6.82 are the warning levels for deal optimism.

What could Trian do next?

ActivTrades identified three possible paths for Trian: improve the offer, launch a proxy fight to change the board, or accept Wendy’s transformation plan. The source assigns no probabilities, financing terms or timetable to those options. The central question, according to the analysis, is whether Wendy’s can restore growth and margins independently or whether shareholder pressure forces a transaction at a higher price. ActivTrades also warned that progress or breakdown in negotiations could produce sharp share-price moves. ActivTrades itself cautions that the material is a marketing communication rather than independent investment research, carries no warranty for accuracy or completeness and does not treat past performance or forecasts as reliable indicators. The next measurable tests are a revised bid above $7.35, evidence that the seven-quarter comparable-sales slide has ended, and whether Trian starts a proxy contest before November 3, 2027.